New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePalmitoyl Dipeptide-6 vs Orforglipron

Palmitoyl Dipeptide-6 vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
Not applicable (topical)
~12 hours (once-daily oral dosing)
Admin Route
Topical
Oral
Research
Typical Dose
0.005–0.05% in formulation
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once or twice daily
Once daily
Key Benefits
  • Increases skin firmness and density
  • Stimulates fibronectin and collagen IV production
  • Strengthens the dermal-epidermal junction
  • Reduces skin sagging in mature skin
  • Improves skin texture and smoothness
  • Supports extracellular matrix integrity
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Generally well-tolerated
  • Rare mild skin irritation in sensitive individuals
  • No known systemic effects at cosmetic concentrations
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With